BioCentury | Jun 29, 2017
Translation in Brief

Tilt a flavin

...and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO)...
...the treatment of acute pancreatitis" Journal of Medicinal Chemistry (2017) Winnie Pong, Staff Writer GSK065(C1) GlaxoSmithKline plc University of Edinburgh Kynurenine 3-monoxygenase (KMO) Pancreatitis...
BioCentury | Jun 27, 2017
Distillery Techniques

Drug platforms

...see “Tilt a Flavin.” BioCentury Innovations (June 29, 2017)). DESCRIPTION: Structural analyses of Pseudomonas fluorescens kynurenine 3-monoxygenase (KMO)-inhibitor...
...online June 12, 2017 doi:10.1038/ncomms15827 CONTACT: Chun-wa Chung, GlaxoSmithKline plc, Stevenage, U.K. email: cc16943@gsk.com Winnie Pong GlaxoSmithKline plc Kynurenine 3-monoxygenase (KMO)...
BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Kynurenine 3-monoxygenase (KMO)

...compared with vehicle. Next steps could include improving the potency of the KMO inhibitor. TARGET/MARKER/PATHWAY: Kynurenine 3-monoxygenase (KMO)...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Kynurenine 3-monoxygenase (KMO)

...and 3-HK compared with vehicle. Ongoing work includes toxicological studies of the KMO inhibitors. TARGET/MARKER/PATHWAY: Kynurenine 3-monoxygenase (KMO)...
BioCentury | Jul 14, 2011
Cover Story

Gladstone's AD venture

...candidate for development by the new AD center is JM6, a small molecule inhibitor of kynurenine 3-monoxygenase (KMO)...
BioCentury | Jun 30, 2011
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Kynurenine 3-monoxygenase (KMO) Studies in...
Items per page:
1 - 6 of 6